ESMO Study Reviews Combination Treatment for T-cell Lymphoma

By Adam Hochron
Save to PDF By

Researchers looking at treatment for relapsed or refractory peripheral T-cell lymphoma described the current prognosis as “dismal.”

To improve patient care, the researchers looked at the safety and efficacy of combining PD1 blockade camrelizumab with anti-angiogenic apatinib. 

Results of the trial, presented at the ESMO Virtual Congress and published in Annals of Oncology, looked at objective response rate and progression-free survival as the two key endpoints. 

The trial included 15 patients. Four with peripheral T-cell lymphoma, four with angioimmunoblastic T-cell lymphoma, two with anaplastic large-cell lymphoma, and five with extranodal NK/T-cell lymphoma nasal type. 

All patients enrolled in the trial were treated with 200 mg of camrelizumab every two weeks and a 28-day cycle of 500 mg of apatinib, “until the evaluation of disease progression, unaccepted toxicity, withdrawal, or death,” according to a release on the study. 

The release noted that 36.4% of evaluable patients achieved overall response rate, including one who achieved complete response. Three patients also achieved partial response, while three “were evaluated with stable disease.” 

The median progression-free survival was 5.47 months, with a range of 0.97 months to 7.37 months.

The researchers noted that “patients with ALCL and ENTKL had more critical benefits compared with other subtypes,” and that all patients with ALCL and two evaluable ENTKL patients had remission. 

Most adverse events reported during the trial were grades one or two, according to the authors. Grade 3 adverse events included thrombocytopenia, neutropenia, hypertension, and rash. There were no adverse events higher than grade 3 reported during the trial.

 

© 2024 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use | Editorial Policy | Advertising Policy